Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Annual Review of Cancer Biology is Scopus-indexed (Q1, CiteScore 10), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Annual Reviews Inc..
Checked against the index lists dated .
ISSN 2472-3428Verify ISSN ↗
Publisher: Annual Reviews Inc.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 53 / 428 | 87th | Q1 |
| Cell Biology | 54 / 289 | 81st | Q1 |
| Cancer Research | 49 / 233 | 79th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2022–present (also 2017–2020), best quartile Q1, CiteScore 10.
Annual Review of Cancer Biology is Q1 in Oncology (rank 53 of 428), Q1 in Cell Biology (rank 54 of 289) and Q1 in Cancer Research (rank 49 of 233), by CiteScore 2025.
Annual Review of Cancer Biology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 10, which places it in quartile Q1 at the 87th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.724, quartile Q1, with an H-index of 44.
Annual Review of Cancer Biology is published by Annual Reviews Inc. Its ISSN is 2472-3428.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Annual Review of Cancer Biology has an h-index of 51 and a 2-year mean of 4.05 citations per paper (OpenAlex). Its Scopus CiteScore is 10, quartile Q1. On 2-year citations it ranks #81 of 424 Scopus journals in Oncology.
Annual Review of Cancer Biology published 22 papers in 2025; its busiest recent year was 2023 with 29. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2021–2026), authors are most often from United States (74%), United Kingdom (9.2%) and Germany (3.2%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.